E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
geographic atrophy secondary to dry age-related macular degeneration |
|
E.1.1.1 | Medical condition in easily understood language |
geographic atrophy secondary to dry age-related macular degeneration |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 27.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10075567 |
E.1.2 | Term | Dry age-related macular degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD) |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Ophthalmic Inclusion Criteria The following inclusion criteria apply to the study eye (SE), one study eye per patient. If both eyes satisfy the inclusion criteria, it is in the investigator's discretion to determine the SE. - Non-foveal GA secondary to dry AMD. - The atrophic lesion must be able to be photographed in its entirety. - Best corrected visual acuity in the SE between 20/25 – 20/320, inclusive.
General Inclusion Criteria - Patients of either gender aged ≥ 50 years. - For patients who are women of childbearing potential involved in any sexual intercourse that could lead to pregnancy, the patient has used a protocol approved highly effective contraceptive method during the trial and agrees to continue the same method until at least 90 days following the last dose of test medication. Protocol approved highly effective contraceptive methods are hormonal contraceptives (i.e., combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, abstinence as defined by refraining from heterosexual intercourse during the entire period of the study and until at least 90 days following the last dose of study medication, vasectomy, and tubal ligation. A woman of non-childbearing potential is defined as follows: • A woman who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) • A woman ≥ 60 years of age A woman ≥ 40 and < 60 years of age who fulfills at least one of the following: - A cessation of menses for at least 12 months and a follicle stimulating hormone (FSH) test confirming non-childbearing potential (refer to laboratory reference ranges for confirmatory levels) - A cessation of menses for at least 24 months without FSH levels confirmed If the patient is a woman of childbearing potential, she must have a negative serum pregnancy test within 14 days prior to the first injection and have no plans to donate ova during the duration of the trial and at least 90 days following the last dose of test medication. Ireland, Slovakia, United Kingdom, Czech Republic, Poland, France, Italy: If the patient is male, he should use a condom and not donate sperm during the time of study drug exposure and for 90 days following the last exposure of study drug - Provide written informed consent. - Ability to return for all trial visits. |
|
E.4 | Principal exclusion criteria |
Patients will not be eligible for the trial if patients cannot attend all trial required visits, or if any of the following criteria are present systemically or in the SE: Ophthalmic Exclusion Criteria The following exclusion criteria apply to the SE: Evidence of CNV in either eye. - Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals. - Any ocular condition in the SE that would progress during the course of the study that could affect central vision or otherwise be a confounding factor. - Presence of other causes of choroidal neovascularization - Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region, regardless of indication. - Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks. - Any sign of diabetic retinopathy in either eye. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Endpoint: The mean rate of growth (slope) estimated based on GA area measured by FAF in at least 3 time points: Baseline, Month 6, and Month 12 (square root transformation)
Safety Endpoints: • AEs • Vital signs (pulse, systolic and diastolic blood pressure) • Ophthalmic variables (BCVA, LLBCVA, IOP, and ophthalmic examination) • ECG (12-lead) • Laboratory variables (blood: hematology, renal function, hepatic function, and electrolytes; urinalysis) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, Month 6, and Month 12 |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Zimura and sham administered by an unmasked investigator |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 106 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Colombia |
Australia |
Brazil |
Canada |
Israel |
United Kingdom |
United States |
Austria |
Belgium |
Croatia |
Czechia |
Denmark |
Estonia |
France |
Germany |
Hungary |
Ireland |
Italy |
Latvia |
Netherlands |
Poland |
Portugal |
Slovakia |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 5 |